Contineum Therapeutics, Inc. Financials

CTNM

All currency values in $ millions unless otherwise noted

Income Statement	TTM	DEC 2025 ~1.4:1 split	DEC 2024 ~5.7:1 split	DEC 2023
Revenues
Revenue	$50	–	$0	$50
General & Administrative	$9	$17	$12	$6
Research & Development	$34	$52	$38	$28
Total Operating Expenses	$43	$68	$51	$34
Operating Income	$7	-$68	-$51	$16
Non-Operating
Net Interest Expense	$7	$8	$9	$4
Other Non-Operating Income (Expense)	$3	-$0	-$0	$3
EBT (Earnings Before Tax)	$17	-$60	-$42	$23
Income Tax Expense	$1	$0	$0	$0
Net Income
Net Income	$16	-$60	-$42	$23
Per Share Data
Revenue Per Share	$1.94	–	$0.00	$14.73
EPS (Basic)	-$0.92	-$2.17	-$2.18	$1.36
EPS (Diluted)	-$2.64	-$2.17	-$2.18	$0.08
Weighted Avg Shares (Basic)	25.7M	27.7M	19.4M	2.3M
Weighted Avg Shares (Diluted)	25.7M	27.7M	19.4M	3.4M
Shares Outstanding	25.7M	27.7M	19.4M	3.4M

Contineum Therapeutics (CTNM) financials: revenue, profit and margins

Contineum Therapeutics (CTNM) generated about n/a in revenue and -$63 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Contineum Therapeutics profitable?+

Contineum Therapeutics reported about -$63 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on CTNM: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 3 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 4 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CTNM

CompareIntrinsic value

KALVKalVista Pharmaceuticals Inc.

No recent price25

XOMAXOMA Corporation

€0.05-3.60%64

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

SPROSpero Therapeutics Inc.

$1.07+2.88%63

GOSSGossamer Bio Inc.

$9.40+1.29%10

SIGASiga Technologies Inc.

$3.15+1.29%20

QTTBQ32 Bio Inc.

$8.97+2.40%60

Held by ETFs

CTNM is in 10 US ETFs. The largest of them, with CTNM's weight in each:

Spot a number that looks wrong? Check it in CTNM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CTNM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.